Abstract
Inflammatory bowel disease affects young population in the fertile age, there is a reason that questions focusing on impact of therapeutic proceedings on pregnancy course and foetus development, are a common aspect in real clinical practice. In the conventional therapy only methotrexate is contraindicated in pregnant women and there are recommendation of stopping metotrexate therapy at least 3-6 monthly before conception.
The anti-TNF biologic agents comprise a monoclonal antibodies application which is not associated with teratogenic effects. These drugs might be used in pregnancy and in lactation without any concerns and fears.
New biologics (vedolizumab/ustekinumab) which have been introduced in the clinical practice recently, don't exhibit any negative signals regarding course of gravidity and foetus development, but experiences are very limited at these time.